SAN
DIEGO, May 14, 2024 /PRNewswire/ -- Element
Biosciences, Inc., developer of pioneering technologies to empower
science, today announced record growth in installations of its
AVITI™ System ahead of its participation in upcoming investor
conferences.
Element has now received more than 200 cumulative orders of
AVITI – the sequencer that provides the highest quality sequencing
on a benchtop for as low as $200 per
genome. In just one year, the company's installed base has grown
from more than 20 units to more than 150. Element's sequencers now
empower research across academia, biotech, cancer research, and
agricultural science in more than 25 countries.
Senior executives, including Molly
He, CEO and Co-founder, and Logan
Zinser, SVP of Finance, will share the news of the company's
continued growth at the following upcoming investor
conferences:
- Bank of America Merrill Lynch Global Healthcare Conference 2024
(Las Vegas – May 14–16)
- Jefferies Global Healthcare Conference (New York – June 5–6)
- Goldman Sachs 45th Annual Global Healthcare
Conference (Miami – June
10–13)
- Morgan Stanley 22nd Annual Global Healthcare
Conference (New York – September
4–6)
- UBS Global Healthcare Conference (Rancho Palos Verdes, CA – November 11–14)
- Stifel Healthcare Conference 2024 (New York – November 18–19)
"Our founding vision was to increase access to high-quality,
affordable tools to help people own their own biology research,
regardless of how well they are funded," said Element CEO
Molly He. "AVITI as our first
product is now being used across the world to expand scientific
possibilities, driving unprecedented growth for Element. Now we aim
to expand this mission beyond sequencing to maximize scientific
information and support the next wave of discovery to ultimately
understand the underlying biology of all species."
Later this year, Element will introduce groundbreaking new
technology to the field through AVITI24™– an innovative,
dual-function platform integrating state-of-the-art sequencing and
multiomic cell analysis. Also launching this year is Trinity™,
Element's on-board enrichment solution that could revolutionize
targeted sequencing for clinical research by radically simplifying
the workflow.
"Our technologies aren't merely driving business expansion,"
Molly He added, "they're empowering
researchers to tackle complex biological problems and make
transformative discoveries."
About Element Biosciences, Inc.
Element Biosciences is
a pioneering life science company democratizing access to advanced
biological tools, driving impactful discoveries to benefit
humanity. We are focused on developing disruptive DNA sequencing
and multi-omics technology for research markets. Through innovating
every fundamental element of a biological assay system, Element
empowers customers with affordable, high-quality data and an
improved user experience, which in turn will accelerate scientific
discoveries. To learn more about Element, please visit
www.elementbiosciences.com and follow us on LinkedIn, X (Twitter),
and Facebook.
Media Contact:
Kristi Heim
Element Biosciences
Kristi.Heim@elembio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/element-biosciences-announces-record-sequencer-installation-growth-ahead-of-participation-in-investor-conferences-302144164.html
SOURCE Element Biosciences